Artiva Biotherapeutics raised $167 million in an IPO to fund cell therapy clinical trials for autoimmune diseases. Their therapy, AlloNK, made from donor cells, is being tested in lupus patients and other autoimmune conditions. The company believes it is the first to receive FDA approval for an allogeneic NK cell therapy in autoimmune disease. Artiva was founded in 2019 and has raised $222.4 million in funding. The company had a previous partnership with Merck for cancer research, which was terminated, and is now working with Affimed on a clinical trial for Hodgkin lymphoma.
Source link
Artiva’s IPO Reels In $167M to Bring NK Cell Therapy to Autoimmune Diseases
